RNA Analysis Market: Trends, Growth Drivers, and Regional Outlook
The global RNA analysis market has become a cornerstone of modern life sciences, enabling researchers and clinicians to study gene expression, regulation, and cellular function with unprecedented precision. RNA analysis covers a broad spectrum of tools and technologies used to study and quantify RNA molecules, including mRNA, miRNA, and other non-coding RNAs. These insights are critical for advancing molecular diagnostics and drug development, particularly for early disease detection and personalized treatment strategies. The global RNA analysis market size was valued at USD 9.64 billion in 2025 and is projected to grow from USD 10.43 billion in 2026 to USD 19.03 billion by 2032, registering a CAGR of 7.80% during the forecast period, according to Fortune Business Insight.
Market Drivers
The primary driver behind this growth is the accelerating shift toward precision medicine and oncology genomics. As the prevalence of genetic diseases and cancer continues to rise, patients and healthcare providers are increasingly turning to treatment options tailored to individual genetic profiles and tumor biology. RNA analysis plays a pivotal role in the early diagnosis and prognosis of cancer, supporting the development of RNA-based targeted therapies that improve treatment efficacy while minimizing adverse effects.
Key industry players are responding to this demand by expanding their portfolios of RNA-based diagnostic and therapeutic tools. A notable example of this momentum came in October 2025, when Novartis acquired Avidity Biosciences, Inc. to strengthen its late-stage neuroscience pipeline with RNA therapeutics. Similarly, in September 2025, Tempus AI, Inc. received FDA 510(k) clearance for its RNA-based Tempus xR IVD device, which supports drug development programs for solid tumors and hematologic malignancies.
Market Restraints and Challenges
Despite strong growth prospects, the market faces certain headwinds. Product recalls involving RNA analysis instruments and devices can damage brand reputation and erode consumer trust, ultimately dampening demand from laboratories and research institutions. For instance, a 2023 FDA warning about a cybersecurity vulnerability in software used by several Illumina sequencing devices highlighted the risks associated with device security in clinical genetic diagnostics.
Additionally, the market contends with a shortage of skilled bioinformaticians and computational biologists capable of designing reliable workflows and interpreting complex RNA data. This talent gap often forces laboratories to outsource analyses, increasing costs and creating friction in adoption.
Emerging Opportunities and Trends
The rising prevalence of neurological, infectious, and cardiovascular diseases is opening new growth avenues for RNA sequencing and analysis technologies. In December 2025, Circular Genomics, Inc. secured USD 15.0 million in funding to advance a circular RNA-based biomarker platform for early Alzheimer's disease detection, illustrating the expanding application scope of RNA analysis beyond oncology.
A key trend reshaping the market is the development of single-cell and spatial transcriptomics, which address longstanding limitations around cost, workflow complexity, and sensitivity in detecting rare transcripts. These technologies offer higher throughput and enhanced spatial resolution, giving researchers more detailed insights into cellular functions and tissue architecture. In March 2025, Singleron Biotechnologies launched MobiuSCOPE, a single-cell RNA sequencing kit capable of full-length transcript analysis, enhancing detection of cellular heterogeneity and novel biomarkers.
Segmentation Insights
By product type, the reagents & consumables segment held the dominant market share in 2025, fueled by increasing R&D activity and new product launches, according to Fortune Business Insight. The instruments segment is expected to grow at a CAGR of 6.87% during the forecast period.
In terms of technology, sequencing-based technologies led the market with a 38.25% share in 2025, according to Fortune Business Insight, driven by rising adoption for genomic research and continuous innovation, such as Roche's February 2025 launch of its Sequencing by Expansion (SBX) technology.
By application, drug discovery & development held the largest share at 29.80% in 2025, according to Fortune Business Insight, while the clinical diagnostics segment is forecasted to grow at 9.40% during the forecast period.
By end user, pharmaceutical & biotechnology companies accounted for 38.6% of the market share in 2025, according to Fortune Business Insight, supported by rising funding activity for RNA therapeutics development.
Regional Outlook
North America dominated the global market with a 51.8% share in 2025, according to Fortune Business Insight, valued at USD 4.99 billion and rising to USD 5.41 billion in 2026. This leadership is underpinned by strong research funding, biotechnology investment, and the presence of major industry players. The U.S. alone accounted for USD 4.75 billion in 2025.
Europe is projected to be the second-fastest-growing region, with a CAGR of 7.59% and a market value of USD 2.49 billion in 2025, according to Fortune Business Insight. The U.K., Germany, and France are expected to reach valuations of USD 0.54 billion, USD 0.50 billion, and USD 0.40 billion respectively in 2025.
Asia Pacific ranked as the third-largest region, reaching USD 1.53 billion in 2025, according to Fortune Business Insight, driven by expanding genomics research and healthcare infrastructure investment across the region.
Competitive Landscape
The market remains fragmented, with numerous companies competing on the strength of their product portfolios and R&D capabilities. Thermo Fisher Scientific Inc., Illumina Inc., and Agilent lead the competitive landscape, while Bio-Rad Laboratories and Bruker maintain a strong presence through diverse assay kits and reagent offerings. Recent developments include Lexogen's October 2025 launch of the miRVEL Profiling Small RNA-Seq Library Prep Kit and Bio-Rad's June 2024 introduction of the ddSEQ Single-Cell 3' RNA-Seq Kit.
Conclusion
The RNA analysis market is positioned for sustained growth through 2032, propelled by advances in precision medicine, expanding applications in neurological and infectious disease research, and continuous innovation in sequencing and transcriptomics technologies. While challenges around skilled talent and device security persist, the market's trajectory reflects the growing importance of RNA-based tools in both research and clinical settings.
What's Driving Japan's Market? Discover the Latest "RNA Analysis" Insights
https://www.fortunebusinessinsights.com/jp/rna%E8%A7%A3%E6%9E%90%E5%B8%82%E5%A0%B4-115023